Eriko Ogino
Research Subjects
Eriko Ogino has a total of 43 co-authors. Here are the top co-authors by number of shared publications:
Juichi Ito
Department of Otolaryngology Head and Neck Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan
8 shared publicationsHarukazu Hiraumi
Department of Otolaryngology, Head and Neck Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan
3 shared publications- Norio Yamamoto
Department of Otolaryngology‐Head and Neck Surgery Kobe City Medical Center General Hospital Kobe Japan
3 shared publications - Tatsunori Sakamoto
Department of Otolaryngology, Head and Neck Surgery, Graduate School of Medicine, Kyoto University
3 shared publications - Harukazu Hiraumi
Department of Otolaryngology, Head and Neck Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan
2 shared publications - Hiro-Oki Okamura
Departments of Otorhinolaryngology
2 shared publications
Latest Publications
- 4 June 2026
- Published by Elsevier in Respiratory Investigation
- Vol. 64 (4) , 101465
Clinical outcome following benralizumab discontinuation in patients with severe eosinophilic asthma: A single-center study
- 4 June 2026
- Published by Elsevier in Respiratory Investigation
- Vol. 64 (4) , 101465
Clinical outcome following benralizumab discontinuation in patients with severe eosinophilic asthma: A single-center study
- 13 February 2025
- Published by Elsevier in Respiratory Investigation
- Vol. 63 (3) , 247-251
Eosinophilic chronic rhinosinusitis as a predictor of super-responder and clinical remission in patients with uncontrolled type 2-high severe asthma treated with biologics
- 13 February 2025
- Published by Elsevier in Respiratory Investigation
- Vol. 63 (3) , 247-251
Eosinophilic chronic rhinosinusitis as a predictor of super-responder and clinical remission in patients with uncontrolled type 2-high severe asthma treated with biologics
- 11 August 2023
- Published by Elsevier in Auris Nasus Larynx
- Vol. 51 (1) , 61-68
Evaluation of odor recognition threshold measurement methods in T&T olfactometry: A survey study
- 11 August 2023
- Published by Elsevier in Auris Nasus Larynx
- Vol. 51 (1) , 61-68
Evaluation of odor recognition threshold measurement methods in T&T olfactometry: A survey study
- Open Access
- 20 July 2023
- Published by Oto-Rhino-Laryngological Society of Japan, Inc. in Nippon Jibiinkoka Tokeibugeka Gakkai Kaiho(Tokyo)
- Vol. 126 (7) , 863-870
Evaluation of Severity of COVID-19 Olfactory Dysfunction Using CT Imaging and Analysis of Predictors of The Prognosis
COVID-19 嗅覚障害は従来の感冒後嗅覚障害とは異なる臨床像を呈することが判明してきた. その一つに CT 画像上での嗅裂所見がある. われわれは, CT 画像での嗅裂所見に注目し, 臨床研究を行った. 対象96症例に対し, CT 上の嗅裂の閉塞なし, ありの2群に分けて, 年齢, 性別, COVID-19 と診断され, 嗅覚障害を自覚した日から受診までの日数 (以下, 発症から受診までの日数), 異嗅症の有無, 嗅覚障害程度について調査した. 嗅覚検査は Visual analogue scale (VAS), 日常のにおいのアンケート, 基準嗅力検査, 静脈性嗅覚検査 (アリナミンテスト), スティック型嗅覚検査 (odor stick identification test for Japanese: OSIT-J) を行った. さらに, 経過を追えた23例に対し, 嗅覚障害改善の予測因子について探索した. CT での嗅裂閉塞あり群の症例では閉塞なし群より嗅覚障害の程度は高度であった. 治癒までの経過を追えた23症例で, 発症から受診までの日数が予後の予測因子となった. 嗅裂の閉塞所見を認める症例では, 嗅覚障害の程度は閉塞なし群の症例より高度であった. 今回の調査では, 経過を追えた症例での予後因子は発症から受診までの日数となり, 治療の早期加入が必要であること, もしくは嗅覚障害が遷延する症例は難治性が多いことが推測された.
- 20 July 2023
- Published by Oto-Rhino-Laryngological Society of Japan, Inc. in Nippon Jibiinkoka Tokeibugeka Gakkai Kaiho(Tokyo)
- Vol. 126 (7) , 863-870
Open AccessEvaluation of Severity of COVID-19 Olfactory Dysfunction Using CT Imaging and Analysis of Predictors of The Prognosis
COVID-19 嗅覚障害は従来の感冒後嗅覚障害とは異なる臨床像を呈することが判明してきた. その一つに CT 画像上での嗅裂所見がある. われわれは, CT 画像での嗅裂所見に注目し, 臨床研究を行った. 対象96症例に対し, CT 上の嗅裂の閉塞なし, ありの2群に分けて, 年齢, 性別, COVID-19 と診断され, 嗅覚障害を自覚した日から受診までの日数 (以下, 発症から受診までの日数), 異嗅症の有無, 嗅覚障害程度について調査した. 嗅覚検査は Visual analogue scale (VAS), 日常のにおいのアンケート, 基準嗅力検査, 静脈性嗅覚検査 (アリナミンテスト), スティック型嗅覚検査 (odor stick identification test for Japanese: OSIT-J) を行った. さらに, 経過を追えた23例に対し, 嗅覚障害改善の予測因子について探索した. CT での嗅裂閉塞あり群の症例では閉塞なし群より嗅覚障害の程度は高度であった. 治癒までの経過を追えた23症例で, 発症から受診までの日数が予後の予測因子となった. 嗅裂の閉塞所見を認める症例では, 嗅覚障害の程度は閉塞なし群の症例より高度であった. 今回の調査では, 経過を追えた症例での予後因子は発症から受診までの日数となり, 治療の早期加入が必要であること, もしくは嗅覚障害が遷延する症例は難治性が多いことが推測された.
- 1 January 2017
- Published by Oto-Rhino-Laryngological Society of Japan, Inc. in Nippon Jibiinkoka Gakkai Kaiho
- Vol. 120 (9) , 1155-1164
Reliability, Validity and Responsiveness of the Sino-Nasal Outcome Test (SNOT-22) in Japanese Patients
- 1 January 2017
- Published by Oto-Rhino-Laryngological Society of Japan, Inc. in Nippon Jibiinkoka Gakkai Kaiho
- Vol. 120 (9) , 1155-1164
Reliability, Validity and Responsiveness of the Sino-Nasal Outcome Test (SNOT-22) in Japanese Patients
- Open Access
- 31 October 2012
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 7 (10) , e48544
Identification of Tympanic Border Cells as Slow-Cycling Cells in the Cochlea
Mammalian cochlear sensory epithelial cells are believed to possess minimal regenerative potential because they halt proliferation during late stage of embryogenesis and never regenerate after birth. This means that sensorineural hearing loss caused by the death of cochlear sensory epithelial cells is a permanent condition. However, stem cells were recently identified in neonatal mice following dissociation of their inner ear organs. This suggests that regenerative therapy for sensorineural hearing loss may be possible. Unfortunately, dissociation distorts the microanatomy of the inner ear, making it difficult to determine the precise location of stem cells in unaltered specimens. To develop new therapeutic approaches based on sensory epithelial cell regeneration, the location of these stem cells must be elucidated. Stem cells normally proliferate at a slow rate in adult organs. In fact, so-called label-retaining cells, or slow-cycling cells, of the brain and skin are recognized as stem cells. In this study, using the exogenous proliferation marker, 5′-bromo-2′-deoxyuridine (BrdU) in combination with the endogenous proliferation marker Ki-67, we identified tympanic border cells. These cells, which are located beneath the basilar membrane in vivo, represent slow-cycling cells of the murine cochlea. Immunohistochemically, these cells stained positive for the immature cell marker Nestin. But it will be difficult to achieve regeneration of the cochlear function because these slow-cycling cells disappear in the mature murine cochlea.
- 31 October 2012
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 7 (10) , e48544
Open AccessIdentification of Tympanic Border Cells as Slow-Cycling Cells in the Cochlea
Mammalian cochlear sensory epithelial cells are believed to possess minimal regenerative potential because they halt proliferation during late stage of embryogenesis and never regenerate after birth. This means that sensorineural hearing loss caused by the death of cochlear sensory epithelial cells is a permanent condition. However, stem cells were recently identified in neonatal mice following dissociation of their inner ear organs. This suggests that regenerative therapy for sensorineural hearing loss may be possible. Unfortunately, dissociation distorts the microanatomy of the inner ear, making it difficult to determine the precise location of stem cells in unaltered specimens. To develop new therapeutic approaches based on sensory epithelial cell regeneration, the location of these stem cells must be elucidated. Stem cells normally proliferate at a slow rate in adult organs. In fact, so-called label-retaining cells, or slow-cycling cells, of the brain and skin are recognized as stem cells. In this study, using the exogenous proliferation marker, 5′-bromo-2′-deoxyuridine (BrdU) in combination with the endogenous proliferation marker Ki-67, we identified tympanic border cells. These cells, which are located beneath the basilar membrane in vivo, represent slow-cycling cells of the murine cochlea. Immunohistochemically, these cells stained positive for the immature cell marker Nestin. But it will be difficult to achieve regeneration of the cochlear function because these slow-cycling cells disappear in the mature murine cochlea.
- 1 August 2012
- Published by Wolters Kluwer Health in Otology & Neurotology
- Vol. 33 (6) , 941-946
Audiometric Outcomes of Topical IGF1 Treatment for Sudden Deafness Refractory to Systemic Steroids
Objective To examine the effects of topically applied recombinant human insulin-like growth factor 1 (IGF1) via gelatin hydrogels on alterations in pure-tone audiometry (PTA) in patients with sudden sensorineural hearing loss (SSHL) refractory to systemic steroids. Study Design Retrospective chart review. Setting A single university hospital. Patients Twenty-five patients with SSHL refractory to systemic steroids who received topical IGF1 treatment. Intervention Single topical application of IGF1 to the round window niche using gelatin hydrogels. Main Outcome Measures The primary outcome was alterations in PTA thresholds at frequencies of 0.25, 0.5, 1, 2, and 4 kHz after topical IGF1 application. Secondary outcomes included differences in final improvements in PTA thresholds among frequencies tested and cumulative numbers of patients showing 10- or 20-dB recovery in PTA during the observation period. Results Topical IGF1 application via gelatin hydrogels significantly altered PTA thresholds at each frequency tested and at the average frequency. The numbers of patients with a 10-dB recovery in PTA increased until 4 weeks after treatment and then stabilized, whereas those patients showing 20-dB recovery gradually increased during the observation period. Conclusion Topical IGF1 application via gelatin hydrogels contributes to the recovery of PTA levels in patients with SSHL refractory to systemic steroids. Major recovery of PTA levels occurs within 4 weeks after treatment.
- 1 August 2012
- Published by Wolters Kluwer Health in Otology & Neurotology
- Vol. 33 (6) , 941-946
Audiometric Outcomes of Topical IGF1 Treatment for Sudden Deafness Refractory to Systemic Steroids
Objective To examine the effects of topically applied recombinant human insulin-like growth factor 1 (IGF1) via gelatin hydrogels on alterations in pure-tone audiometry (PTA) in patients with sudden sensorineural hearing loss (SSHL) refractory to systemic steroids. Study Design Retrospective chart review. Setting A single university hospital. Patients Twenty-five patients with SSHL refractory to systemic steroids who received topical IGF1 treatment. Intervention Single topical application of IGF1 to the round window niche using gelatin hydrogels. Main Outcome Measures The primary outcome was alterations in PTA thresholds at frequencies of 0.25, 0.5, 1, 2, and 4 kHz after topical IGF1 application. Secondary outcomes included differences in final improvements in PTA thresholds among frequencies tested and cumulative numbers of patients showing 10- or 20-dB recovery in PTA during the observation period. Results Topical IGF1 application via gelatin hydrogels significantly altered PTA thresholds at each frequency tested and at the average frequency. The numbers of patients with a 10-dB recovery in PTA increased until 4 weeks after treatment and then stabilized, whereas those patients showing 20-dB recovery gradually increased during the observation period. Conclusion Topical IGF1 application via gelatin hydrogels contributes to the recovery of PTA levels in patients with SSHL refractory to systemic steroids. Major recovery of PTA levels occurs within 4 weeks after treatment.
- Open Access
- 2 July 2012
- Published by Wiley in The Laryngoscope
- Vol. 122 (10) , 2154-2157
An endoscopic endonasal surgery training model using quail eggs
- 2 July 2012
- Published by Wiley in The Laryngoscope
- Vol. 122 (10) , 2154-2157
Open AccessAn endoscopic endonasal surgery training model using quail eggs
- 5 April 2012
- Published by Wiley in The Laryngoscope
- Vol. 122 (6) , 1392-1396
Effect of cisplatin on distortion product otoacoustic emissions in Japanese patients
Objectives/Hypothesis: Although it is well known that cisplatin is associated with ototoxicity, there is still a lack of knowledge concerning the ototoxicity of cisplatin, especially in Japanese head and neck cancer patients. The objectives of this study were to determine the incidence rate of cisplatin ototoxicity and to determine the threshold dose causing ototoxicity in the Japanese population.Study Design: Before‐and‐after study in a tertiary referral hospital.Methods: The distortion product otoacoustic emission (DPOAE) was measured 1 week after each administration of cisplatin in 44 Japanese head and neck cancer patients treated at Kyoto University Hospital. We determined the incidence and threshold dose of cisplatin ototoxicity according to DPOAE data.Results: The incidence of ototoxicity detected by DPOAE was 77.3%. The average DPOAE value was significantly lower in patients who received more than 200 mg/m2 cisplatin than the baseline DPOAE value. The threshold dose for cisplatin ototoxicity was lower in Japanese patients than in European patients.Conclusions: Our data suggest that Japanese patients are more susceptible to cisplatin‐induced ototoxicity. This is presumably caused by a genetic difference.
- 5 April 2012
- Published by Wiley in The Laryngoscope
- Vol. 122 (6) , 1392-1396
Effect of cisplatin on distortion product otoacoustic emissions in Japanese patients
Objectives/Hypothesis: Although it is well known that cisplatin is associated with ototoxicity, there is still a lack of knowledge concerning the ototoxicity of cisplatin, especially in Japanese head and neck cancer patients. The objectives of this study were to determine the incidence rate of cisplatin ototoxicity and to determine the threshold dose causing ototoxicity in the Japanese population.Study Design: Before‐and‐after study in a tertiary referral hospital.Methods: The distortion product otoacoustic emission (DPOAE) was measured 1 week after each administration of cisplatin in 44 Japanese head and neck cancer patients treated at Kyoto University Hospital. We determined the incidence and threshold dose of cisplatin ototoxicity according to DPOAE data.Results: The incidence of ototoxicity detected by DPOAE was 77.3%. The average DPOAE value was significantly lower in patients who received more than 200 mg/m2 cisplatin than the baseline DPOAE value. The threshold dose for cisplatin ototoxicity was lower in Japanese patients than in European patients.Conclusions: Our data suggest that Japanese patients are more susceptible to cisplatin‐induced ototoxicity. This is presumably caused by a genetic difference.
- 1 January 2012
- Published by The Society of Practical Otolaryngology in Practica Oto-Rhino-Laryngologica
- Vol. 105 (10) , 951-955
A Case of Sphenoid Fibrous Dysplasia Compressing the Orbital Apex
Fibrous dysplasia is a benign proliferative bone disorder and sometimes involves the craniofacial bone including the skull base and orbit. A 40-year-old male presented visual disturbance and headache. Image examinations revealed fibrous dysplasia arising from the sphenoid, which compressed the right orbital apex. Endoscopic endonasal surgery was performed to resect the fibrous dysplasia around the right orbital apex, resulting in improvement of the visual disturbance. The endoscopic endonasal approach may be the primary choice for resection of fibrous dysplasia causing compression of the orbit.
- 1 January 2012
- Published by The Society of Practical Otolaryngology in Practica Oto-Rhino-Laryngologica
- Vol. 105 (10) , 951-955
A Case of Sphenoid Fibrous Dysplasia Compressing the Orbital Apex
Fibrous dysplasia is a benign proliferative bone disorder and sometimes involves the craniofacial bone including the skull base and orbit. A 40-year-old male presented visual disturbance and headache. Image examinations revealed fibrous dysplasia arising from the sphenoid, which compressed the right orbital apex. Endoscopic endonasal surgery was performed to resect the fibrous dysplasia around the right orbital apex, resulting in improvement of the visual disturbance. The endoscopic endonasal approach may be the primary choice for resection of fibrous dysplasia causing compression of the orbit.